Home › Interstitial Lung Diseases › Alabama
Interstitial Lung Diseases clinical trials in Alabama
10 studies for Interstitial Lung Diseases are looking for participants at sites in Alabama.
Cities in Alabama
LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- University of Alabama, Birmingham
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 29, 2026 · NCT05798923FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease Progression
- University of Alabama at Birmingham, Birmingham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07540988A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseases
- University of Alabama at Birmingham, Birmingham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06806592A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
- UAB Lung Health Center, Birmingham
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Sep 4, 2026 · NCT06968845Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
- University of Alabama at Birmingham, Birmingham
Recruiting
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06911632DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- University of Alabama at Birmingham, Birmingham
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT06388421Platform Clinical Study for Conquering Scleroderma
- University of Alabama - Division of Pulmonary and Critical Care Medicine, Birmingham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06195072Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
- University of Alabama - Birmingham, Birmingham
RecruitingObservational study
Ages 21 and older · All sexes · Updated Aug 12, 2026 · NCT01915511Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
- UAB Lung Health Center, Birmingham
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT05943535Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
- University of Alabama at Birmingham, Birmingham
RecruitingPhase 2
Ages 40 and older · All sexes · Updated Nov 12, 2025 · NCT05975983From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.